Prostate cancer's resistance to treatment can be reversed in some patients by stopping hijacked white blood cells from being 'pulled into' tumors, according to new research published in Nature.
Oct 17, 2023
0
55
High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. It is also the most lethal form, in part because clinicians do not have effective ways to screen women for it during the cancer's early ...
Oct 11, 2023
0
53
A new combination of treatments safely decreased growth of pancreatic cancer in mice by preventing cancer cells from scavenging for fuel, a new study finds.
Oct 9, 2023
0
113
Lung cancer is the leading cause of cancer-related deaths in the United States. Some tumors are extremely small and hide deep within lung tissue, making it difficult for surgeons to reach them. To address this challenge, ...
Sep 21, 2023
0
31
Northwestern Medicine investigators have discovered how the protein PD-1 controls essential metabolic processes in tumor cells to promote cancer growth in T-cell non-Hodgkin lymphomas (T-NHLs), according to a study published ...
Sep 21, 2023
0
26
Obesity surgery is associated with a 40% lower risk of hematological cancer. This has been shown in a study from the University of Gothenburg. This clear link is expected to influence future research in the field.
Sep 21, 2023
0
27
Even for killer T cells—specialized immune cells—seeking and destroying cancer cells around the clock can be exhausting. If scientists can understand why killer T cells become exhausted, then they can create more resilient ...
Sep 20, 2023
0
32
Among available immunotherapies, the use of CAR T cells is proving extremely effective against certain blood cancers, but only in half of patients. A main reason for this is the premature dysfunction of these immune cells, ...
Sep 20, 2023
0
26
While immunotherapies have shown great promise in treating blood cancers, most clinical trials aimed at treating solid tumors such as pancreatic or lung cancer have failed. Researchers have long thought that solid tumors' ...
Sep 18, 2023
0
138
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the neoadjuvant (pre-surgical) setting for early-stage non-small-cell lung cancer (NSCLC), ...
Sep 14, 2023
0
66
